Modality
ASO
MOA
JAK1/2i
Target
CD47
Pathway
Apoptosis
Breast Ca
Development Pipeline
Preclinical
~Nov 2014
→ ~Feb 2016
Phase 1
~May 2016
→ ~Aug 2017
Phase 2
Nov 2017
→ May 2029
Phase 2Current
NCT07675340
1,497 pts·Breast Ca
2017-11→2029-05·Completed
1,497 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-05-113.1y awayPh3 Readout· Breast Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2/3
Complet…
Catalysts
Ph3 Readout
2029-05-11 · 3.1y away
Breast Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07675340 | Phase 2/3 | Breast Ca | Completed | 1497 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |